Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2015-04-14 Earnings Release
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 98% confidence The document is titled "Nanobiotix: 2014 Annual Results" and is dated April 14, 2015. It presents audited consolidated results for the fiscal year ended December 31, 2014, including a detailed income statement table comparing 2014 and 2013 figures, and a financial review discussing revenue, R&D costs, and net loss for the year. This content strongly indicates a formal release of annual financial performance data. Although it is a press release announcing the results, its primary function is to deliver the core annual financial summary, making it an Earnings Release (ER) focused on annual results, rather than a comprehensive 10-K filing itself. Since it explicitly details the full year's financial performance highlights and key figures, ER is the most appropriate classification among the options provided, as 10-K is reserved for the official regulatory filing. FY 2014
2015-04-14 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated March 18, 2015, announcing that Nanobiotix has appointed CordenPharma as its manufacturing partner to scale up production of NBTXR3. This announcement relates to operational progress and future commercialization plans, specifically concerning manufacturing capacity and clinical trial timelines. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). It is an announcement concerning business operations and strategic partnerships. Among the provided codes, 'Regulatory Filings' (RNS) is the most appropriate general category for significant, non-standard operational press releases that do not fit the more specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS). Since it is a general business update announcement, RNS serves as the best fit.
2015-03-17 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated March 18, 2015, announcing a strategic partnership between Nanobiotix and CordenPharma for the production of NBTXR3. It details operational steps towards commercialization, capacity increases, and future clinical trials. This type of announcement, focusing on operational milestones, partnerships, and future commercial strategy, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate classification is Earnings Release (ER), as these often accompany or precede formal quarterly/annual reporting periods to highlight key business developments. It is not a Report Publication Announcement (RPA) because it is a substantive announcement about a partnership, not just a notice that a report is available. Given the focus on operational progress leading to commercialization, ER is the best fit among the provided options.
2015-03-17 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of February 28, 2015. This type of mandatory periodic disclosure regarding the capital structure and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER) or specific corporate actions (DIV, SHA, POS). It is a regulatory disclosure concerning share capital structure, which is best categorized as a general Regulatory Filing (RNS) or potentially a specific filing related to capital changes, but RNS serves as the best general regulatory disclosure bucket when a more specific one isn't available among the provided options. Given the options, RNS is the most appropriate fallback for this specific regulatory notice.
2015-03-06 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 98% confidence The document is a press release dated February 19, 2015, announcing that Professor Robert Langer has joined Nanobiotix as a Scientific Advisor. This announcement concerns a change in key personnel/advisors associated with the company's scientific direction. This fits the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management, extending logically to key scientific advisors who influence strategy and development. It is not a formal regulatory filing like a 10-K, an earnings release, or a dividend notice.
2015-02-19 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 98% confidence The document is a press release dated February 19, 2015, announcing that Professor Robert Langer has become a Scientific Advisor to Nanobiotix. It details his credentials and the company's technology (NanoXray). This type of announcement, concerning a change in senior personnel or advisory board members, directly corresponds to the definition of 'Board/Management Information'. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A). Therefore, the appropriate code is MANG.
2015-02-19 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.